AVNS Technical Analysis & Stock Price Forecast
The article provides a technical analysis for Avanos Medical Inc (AVNS), indicating a "Strong Buy" consensus based on various indicators as of April 2, 2026. Key metrics such as MACD, moving averages, and momentum indicators suggest positive short-term momentum, while RSI shows a neutral condition. The stock is trading above its 60-day and 200-day moving averages, with identified support and resistance levels.
AVNS SEC Filings - Avanos Medical 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Avanos Medical (AVNS) SEC filings, including 10-K, 10-Q, and 8-K forms, with AI-powered summaries and sentiment analysis. It details how Avanos uses these filings to report financial performance, strategic actions, and governance matters. The platform also offers real-time access to EDGAR data and AI-generated overviews to help investors quickly understand key information.
AVNS Should I Buy
Intellectia.AI advises against buying Avanos Medical Inc (AVNS) for beginner investors with a long-term strategy, recommending a "Hold" position instead. The analysis is based on mixed technical indicators, weak financial performance in Q4 2025 (including significant drops in net income and EPS), and a lack of strong positive catalysts. While Barclays raised its price target slightly, it's not enough to warrant a strong buy signal, and stock trend analysis predicts a potential decline in the near future.
CFO at Avanos (NYSE: AVNS) awarded new stock options and RSUs
Avanos Medical's SVP and CFO, Scott Michael Galovan, has received new equity awards, including 69,630 employee stock options at an exercise price of $13.69 and 29,481 shares of Common Stock. These awards, granted under the company's 2021 Long Term Incentive Plan, increase his total holdings to 96,212 options and 139,824 direct shares. The common stock awards are time-based restricted share units (TRSUs) that will vest in scheduled installments on March 13, 2027, 2028, and 2029, aligning a portion of his compensation with the company’s long-term performance.
AVNS SEC Filings - Avanos Medical 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Avanos Medical (AVNS) SEC filings, including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms. It highlights how Avanos reports financial performance, strategic actions, and governance matters for its Specialty Nutrition Systems and Pain Management & Recovery segments. The platform enhances disclosures with AI-powered summaries, impact scoring, and sentiment analysis for quick understanding of regulatory documents.
Avanos Medical (NYSE: AVNS) SVP receives new stock options and RSU awards
Avanos Medical's SVP of Operations, Sigfrido Delgado, was granted 37,520 employee stock options with an exercise price of $13.69 and 15,886 time-based restricted share units. These awards, issued under the company's 2021 Long Term Incentive Plan, are compensation and not open-market purchases. The RSUs will vest in installments between March 2027 and March 2029, and following these grants, Delgado holds 59,434 stock options and 60,005 shares of AVNS common stock.
Avanos Medical Inc Stock: Institutional Confidence Builds Amid Pain Management and Acute Care Focus
Avanos Medical Inc is attracting significant institutional investment due to its focus on medical devices for pain management and acute care, particularly in North America. Major funds like JPMorgan Chase & Co. are increasing their stakes, signaling confidence in the company's operational stability, strategic product innovations, and solid financial health. The company's niche in essential hospital consumables and its alignment with long-term healthcare trends position it as a resilient pick for diversified investment portfolios.
Avanos Medical Inc Stock: Institutional Confidence Builds Amid Pain Management and Acute Care Focus
Avanos Medical Inc (NYSE:AVNS) is attracting significant institutional investment due to its focus on medical devices for pain management and acute care. Major funds like JPMorgan Chase & Co. have increased their holdings, signaling confidence in the company's operational stability, product innovation, and undervalued potential within the medtech sector. The company's lean balance sheet, consistent revenue growth, and strategic product portfolio, particularly in opioid-sparing pain relief and respiratory care, position it as a resilient pick for North American investor portfolios.
Avanos (NYSE: AVNS) CFO granted 70,115 options and 29,481 TRSUs
Avanos Medical, Inc. (NYSE: AVNS) CFO, Scott Michael Galovan, received new equity awards comprising 70,115 stock options with an exercise price of $13.69, expiring in 2036, and 29,481 time-based restricted share units (TRSUs). These awards increase his total option holdings to 96,697 and direct common stock holdings to 139,824 shares. The TRSUs will vest in tranches over three years, from 2027 to 2029, as detailed in an amended Form 4 SEC filing.
[Form 4/A] AVANOS MEDICAL, INC. Amended Insider Trading Activity
This article details an amended insider trading activity Form 4/A filing for AVANOS MEDICAL, INC. (AVNS). The filing reports equity compensation grants to CEO David Pacitti, including employee stock options and shares of common stock, with specific vesting schedules. The amendment clarifies a correction in the calculated number of stock options.
Avanos (NYSE: AVNS) grants options and TRSUs to SVP Delgado
Avanos Medical (NYSE: AVNS) has awarded its Senior Vice President of Operations, Sigfrido Delgado, new equity grants. These include 37,782 employee stock options with an exercise price of $13.69 per share and 15,886 time-based restricted share units (TRSUs). The TRSUs will vest in stages between March 2027 and March 2029, and the options have an expiration date of March 13, 2036.
Avanos Medical (NYSE:AVNS) Rating Increased to Buy at Wall Street Zen
Wall Street Zen has upgraded Avanos Medical (NYSE:AVNS) from a "hold" to a "buy" rating, although MarketBeat's consensus remains "Reduce" due to mixed analyst opinions. The company surpassed Q4 earnings estimates with EPS of $0.29 and revenue of $180.9M, and institutional investors now hold approximately 95.17% of the stock. Despite a negative net margin of -10.40%, Avanos Medical reported a positive ROE of 5.47% and provided FY2026 EPS guidance between $0.90–1.10.
Vanguard disaggregates holdings; Avanos (AVNS) shows 0 shares after realignment
The Vanguard Group has filed an amended Schedule 13G/A, reporting 0 shares and 0% beneficial ownership in Avanos Medical Inc (AVNS) following an internal realignment on January 12, 2026. This change means certain Vanguard subsidiaries will now report beneficial ownership separately. The filing clarifies that this is a structural change, not a sale of shares by Vanguard, and does not impact Avanos' operational metrics or financials.
Zacks Research Cuts Earnings Estimates for Avanos Medical
Zacks Research has significantly reduced its Q2 2027 earnings per share estimate for Avanos Medical (NYSE:AVNS) from $0.32 to $0.14, maintaining a "Hold" rating on the stock. Despite beating Q4 2025 earnings and revenue expectations ($0.29 EPS vs. $0.24; $180.9M revenue vs. $174.7M), the company reported a negative net margin and low revenue growth. Institutional investors hold a large stake, with notable increases from Northwestern Mutual and Armistice Capital.
AVANOS MEDICAL unveils RxCrush device aimed at simplifying medication delivery for nurses
AVANOS MEDICAL has launched the RxCrush Pill Crushing System, designed by nurses specifically for nurses to simplify medication delivery. This initiative aims to support healthcare professionals during National Nurses Month and is part of the company's broader efforts to expand its presence in nurse-driven healthcare solutions. The system will be distributed through official AVANOS MEDICAL contacts, reinforcing their commitment to tailored clinical tools.
AVNS Financials: Revenue Breakdown, Margins & Competitor Comparison
This article provides a financial overview of Avanos Medical Inc (AVNS), detailing its revenue breakdown, profitability margins, and a comparison with competitors. The company's primary revenue driver is Digestive Health, contributing 65.9% of total sales. While AVNS maintains a gross margin of 47.54%, its net margin is negative at -0.72%, with a Return on Equity of -9.07%.
Analysts Set Expectations for Avanos Medical FY2026 Earnings
Zacks Research has reduced its FY2026 EPS estimate for Avanos Medical to $1.07, maintaining a "Hold" rating. This is notably lower than the consensus analyst estimate of $1.32 and the company's own guidance of $0.90-$1.10. Despite beating recent quarterly earnings expectations, the company reported a negative net margin, and analyst sentiment remains weak while institutional ownership is high.
Reasons to Retain Avanos Medical Stock in Your Portfolio for Now
Avanos Medical (AVNS) is positioned for growth due to its strong product line, solid performance in core segments like Specialty Nutrition Systems and Pain Management and Recovery, and strategic portfolio optimization including accretive M&A. However, the company faces persistent tariff headwinds, potential margin pressure from tariff-related costs, slower growth in some segments, and execution risks associated with ongoing portfolio restructuring. Despite these challenges, Avanos aims for long-term growth through cost efficiency and a focus on higher-margin sectors.
Reasons to retain Avanos Medical stock in your portfolio for now
This article highlights key reasons to retain Avanos Medical (AVNS) stock, including its strong product portfolio with offerings like the COOLIEF and ON-Q systems, which continue to drive growth. The company's expansion into international markets and its prudent acquisition strategy further solidify its market position, making it a potentially attractive investment.
Reasons to Keep Avanos Medical Shares in Your Investment Portfolio at This Time
Avanos Medical (AVNS) is poised for growth due to its strong medical device portfolio, robust expansion in Specialty Nutrition Systems and Pain Management, and strategic portfolio optimization including M&A activities and divestitures. Despite challenges from tariffs, the company is implementing cost-efficiency measures, and its long-term prospects remain positive. Avanos Medical is seen as a strong investment, with Zacks' estimates for fiscal 2026 holding steady.
Avanos Medical tops Q4 earnings and revenue forecasts
Avanos Medical reported stronger-than-expected earnings and revenue for the fourth quarter. The company's performance exceeded analyst forecasts, indicating a positive close to the fiscal year.
Avanos Medical (NYSE: AVNS) CEO receives new stock options and RSUs
Avanos Medical's CEO, David Pacitti, has been granted new equity awards, including 239,354 employee stock options with an exercise price of $13.69 per share and 101,341 time-based restricted share units (RSUs). These RSUs will vest in three equal installments between March 2027 and March 2029. Following these grants, Pacitti directly holds 343,388 shares of Avanos Medical Common Stock.
Avanos Medical (AVNS) grants SVP Delgado stock options and RSUs
Avanos Medical SVP Sigfrido Delgado was granted employee stock options for 37,520 shares and 15,886 time-based restricted share units on March 13, 2026, as part of his compensation. The stock options have an exercise price of $13.69 and expire in 2036, with vesting occurring in stages between 2027 and 2029. Following these awards, Delgado's direct holdings include 60,005 shares of common stock and 59,434 derivative securities.
Avanos Medical (AVNS) CFO receives new stock options and RSUs
Avanos Medical's CFO, Scott Michael Galovan, has been awarded new stock options and time-based restricted share units (RSUs) as part of his compensation. He received options for 69,630 common shares with an exercise price of $13.69, expiring in 2036, and 29,481 RSUs that will vest in three equal tranches over the next three years. Following these awards, Galovan directly holds 139,824 common shares and 96,212 stock options, aligning his incentives with the company's long-term performance.
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Avanos Medical, Inc. (NYSE: AVNS)
Purcell & Lefkowitz LLP has initiated a shareholder investigation into Avanos Medical, Inc. (NYSE: AVNS) to determine if its directors breached their fiduciary duties regarding recent corporate actions. Shareholders of Avanos Medical are encouraged to contact the firm for more information about their rights and options. The firm specializes in representing shareholders affected by securities fraud and corporate misconduct.
Avanos Medical Inc Stock Faces Analyst Downgrade as FY2026 Guidance Signals Caution
Avanos Medical Inc (ISIN: US05350V1061) has been downgraded to "Hold" by Wall Street Zen following the company's fiscal year 2026 earnings guidance of $0.90 to $1.10 per share, which is significantly below the $1.32 consensus forecast. This downgrade reflects reduced conviction among analysts, despite a high institutional ownership of 95.2%. The conservative guidance suggests potential operational challenges or increased management caution, raising concerns about the medical-device maker's near-term performance.
Cove Street Capital LLC Grows Stock Holdings in Avanos Medical, Inc. $AVNS
Cove Street Capital LLC significantly increased its stake in Avanos Medical, Inc. (NYSE:AVNS) by 430.7% in Q3, now holding 112,081 shares valued at approximately $1.30 million. This move makes Avanos Medical its 26th largest position, with other institutional investors also boosting their holdings, bringing total institutional ownership to about 95.17%. Despite mixed-to-negative analyst sentiment and some recent downgrades, Avanos Medical recently beat earnings estimates and provided optimistic FY2026 EPS guidance.
Avanos Medical Inc Stock Faces Analyst Downgrade as FY2026 Guidance Signals Caution
Avanos Medical Inc (ISIN: US05350V1061) has been downgraded to "Hold" by Wall Street Zen following the release of its conservative FY2026 earnings guidance of $0.90 to $1.10 per share, significantly below the consensus of $1.32. This 24% gap raises concerns about potential operational headwinds, margin pressures, or a strategic shift not yet reflected in the market. The downgrade, despite 95.2% institutional ownership, signals a loss of conviction and advises investors to await further clarity on the company's operational trajectory, as the stock is considered fairly valued but lacks near-term catalysts.
Avanos Medical (NYSE:AVNS) Downgraded by Wall Street Zen to Hold
Wall Street Zen downgraded Avanos Medical (NYSE:AVNS) from "Buy" to "Hold" after the company beat Q4 earnings estimates but provided lower-than-expected FY2026 guidance. Despite institutional ownership of over 95%, the stock carries a "Reduce" consensus rating from MarketBeat based on analyst recommendations. The company's financials include a negative P/E of -8.67 and a 52-week range of $9.30–$15.68.
AVANOS MEDICAL, INC. ($AVNS) CEO 2025 Pay Revealed
AVANOS MEDICAL, INC. ($AVNS) CEO David C. Pacitti's estimated compensation for 2025 was $9,469,803, based on a recent SEC filing. The article also details recent insider trading activity, with four sales and zero purchases in the past six months, government contracts totaling over $1.1 million, and significant institutional investor activity in Q3 and Q4 2025.
AVANOS MEDICAL, INC. ($AVNS) CEO 2025 Pay Revealed
AVANOS MEDICAL, INC. ($AVNS) CEO David C. Pacitti is estimated to have received $9,469,803 in compensation in 2025, based on a recent SEC filing. The article also details insider trading activity, showing 4 sales and 0 purchases by insiders in the last six months, and government contracts totaling over $1.1 million awarded to AVNS in the last year. Additionally, it highlights significant institutional investor activity in Q3 and Q4 2025.
Avanos Medical, Inc. Files Form 8-K with SEC Detailing Corporate Information and Common Stock Listing on NYSE
Avanos Medical, Inc. filed an 8-K report detailing a significant change to its CEO's long-term compensation, increasing the target value of the annual long-term incentive grant for David C. Pacitti. This adjustment, effective in 2026, is seen as a signal of the Board's confidence, a response to competitive pressures, or a reward for past performance. Investors are advised to monitor future company communications for more details on this compensation change and its potential impact on governance and future company performance.
Avanos Medical boosts CEO long-term incentive compensation
Avanos Medical has increased CEO David Pacitti’s annual long-term incentive target from $5 million to $5.5 million, effective 2026. This decision reflects the company's focus on executive retention, aligning leadership performance with shareholder interests, and confidence in Pacitti’s role in future operational and financial success. Despite this, TipRanks' AI Analyst Spark rates AVNS as Neutral due to some financial volatilities, though noting a solid balance sheet and constructive stock trend.
Avanos (NYSE: AVNS) officer surrenders 226 shares to cover RSU tax
Avanos Medical, Inc.'s Principal Accounting Officer, John Joseph Hurley, surrendered 226 shares of common stock to cover tax withholding obligations associated with the vesting of 647 time-based restricted share units on March 9, 2026. The shares were valued at $13.29 each for tax purposes. Following this transaction, Hurley directly holds 11,381 shares of Avanos common stock.
Elastomeric Infusion Pumps Market size to cross $1.95 Billion by 2035 | B. Braun Melsungen AG, Avanos Medical, Inc, Nipro Corporation, Vygon Group, Baxter International Inc
The global Elastomeric Infusion Pumps Market, valued at USD 973.73 million in 2025, is projected to reach approximately USD 1.95 billion by 2035, growing at a CAGR of 7.2%. This growth is driven by the increasing demand for ambulatory infusion systems, rising prevalence of chronic diseases, and expansion of home-based healthcare, particularly in North America, Europe, and the Asia Pacific region. Key market trends include the expansion of home-based healthcare, advancements in pump design, and increasing demand for infection-safe drug delivery systems, with major companies like Baxter International and B. Braun Melsungen AG leading continuous innovation.
[Form 4] AVANOS MEDICAL, INC. Insider Trading Activity
AVANOS MEDICAL, INC.'s SVP and Chief Financial Officer, Scott Michael Galovan, reported equity award activity. On March 6, 2026, he acquired 5,907 shares of common stock through the vesting of performance-based restricted share units and subsequently disposed of shares to cover tax withholding obligations. After these transactions, he directly owned 111,462 shares of Avanos common stock.
Avanos Medical tops Q4 earnings and revenue forecasts
Avanos Medical exceeded its Q4 earnings and revenue forecasts. This positive performance indicates strong financial results for the company during the last quarter of the fiscal year.
Avanos Medical, Inc. to Present at the 2026 Citizens Life Sciences Conference
Avanos Medical, Inc. (NYSE: AVNS) announced that its CEO, Dave Pacitti, and CFO, Scott Galovan, will participate in a fireside chat at the 2026 Citizens Life Sciences Conference on March 11, 2026, at approximately 1:05 p.m. Eastern Time. A webcast of the presentation will be available on the Investors section of the company's website. Avanos Medical is a medical technology company focused on delivering clinically superior medical device solutions to help patients.
Avanos Medical (NYSE:AVNS) Downgraded by Wall Street Zen to Buy
Wall Street Zen has downgraded Avanos Medical (NYSE:AVNS) from a "strong-buy" to a "buy" rating, despite the company beating Q4 2025 earnings and revenue estimates. Avanos Medical reported adjusted EPS of $0.29 against an estimated $0.24 and revenue of $180.9 million versus $174.7 million. However, the company issued lower-than-expected FY2026 EPS guidance, which led to a stock decline of about 2.6% at market open.
Avanos Medical, Inc. Announces Fourth Quarter and Full-Year 2025 Results
Avanos Medical, Inc. (NYSE: AVNS) has released its fourth quarter and full-year 2025 results, reporting a 0.7% increase in Q4 net sales to $180.9 million and a 1.9% increase for the full year to $701.2 million. The company exceeded its full-year revenue and achieved the top end of its earnings-per-share guidance, driven by strong organic growth in its Specialty Nutrition Systems segment. Avanos provided a 2026 outlook, expecting net sales between $700 million and $720 million, and adjusted diluted earnings per share between $0.90 and $1.10.
Avanos Medical (AVNS) Q4 Earnings and Revenues Surpass Estimates
Avanos Medical (AVNS) reported strong Q4 results, surpassing Zacks Consensus Estimates for both earnings and revenues. The company posted earnings of $0.29 per share against an estimate of $0.24, and revenues of $180.9 million, exceeding the $175.94 million consensus. Despite outperforming the market year-to-date, its Zacks Rank #3 (Hold) suggests it's expected to perform in line with the market in the near future.
Avanos Medical, Inc. to Nominate James Cunniff and William Burke to Board of Directors
Avanos Medical, Inc. announced its intention to nominate James L. Cunniff and William P. Burke as independent directors to its Board of Directors at the upcoming 2026 Annual Meeting of Stockholders. This decision follows a cooperation agreement with Bradley L. Radoff. The company believes these additions will enhance the Board's executive leadership and financial expertise, supporting Avanos' strategic priorities and long-term growth.
Avanos Medical (NYSE: AVNS) adds Cunniff, Burke nominees in Radoff pact
Avanos Medical has reached a cooperation agreement with investor Bradley L. Radoff, leading to the nomination of James L. Cunniff and William P. Burke as independent directors at the 2026 annual meeting. In exchange, Radoff withdrew his director nomination and agreed to standstill and voting commitments. This agreement aims to enhance the Board's leadership and financial expertise while ensuring board stability.
Avanos Medical, Inc. to Nominate James Cunniff and William Burke to Board of Directors
Avanos Medical, Inc. announced its intention to nominate James L. Cunniff and William P. Burke as independent directors to its Board of Directors at the 2026 Annual Meeting of Stockholders. This decision follows a cooperation agreement with Bradley L. Radoff, with these nominations aimed at enhancing the Board's executive leadership, financial expertise, and strategic vision. The company believes both individuals bring valuable experience in the medical technology sector crucial for supporting Avanos's strategic priorities and long-term success.
Avanos Medical, Inc. (NYSE:AVNS) Q4 2025 Earnings Call Transcript
Avanos Medical (NYSE:AVNS) reported its Q4 and full-year 2025 earnings, showcasing solid results driven by strategic priorities. The company exceeded net sales guidance with $701 million for the full year and met the high end of its earnings guidance with $0.94 adjusted diluted EPS. Avanos is actively mitigating tariff impacts, including a full exit from China for syringe manufacturing by June 2026, and provided a 2026 outlook of $700 million to $720 million in net sales and $0.90 to $1.10 adjusted diluted EPS.
Avanos Medical, Inc. 2025 Q4 - Results - Earnings Call Presentation (NYSE:AVNS) 2026-02-24
Avanos Medical, Inc. (AVNS) released its Q4 2025 earnings call presentation, reporting an EPS of $0.29, which beat estimates by $0.04. The company's revenue reached $180.90M, surpassing expectations by $6.20M and showing a 0.72% year-over-year increase. This article presents the slide deck from the earnings call.
Avanos Medical Stock Dips Despite Q4 Earnings Beat, Revenues Up Y/Y
Avanos Medical (AVNS) reported a Q4 2025 earnings beat with adjusted EPS of 29 cents, surpassing the Zacks Consensus Estimate, and revenues up 0.7% year-over-year to $180.9 million, also beating estimates. Despite the beat, the company's stock dipped, and its shares have significantly declined year-to-date. The company provided a 2026 sales and EPS outlook, anticipating net sales between $700-$720 million and adjusted EPS between 90 cents and $1.10.
Avanos Medical (AVNS) Margins Stay Negative Reinforcing Bearish Earnings Narratives
Avanos Medical (AVNS) concluded FY 2025 with a Q4 revenue of US$180.9 million and a basic EPS loss of US$0.03, continuing a trend of negative margins. The company's trailing 12-month revenue was US$701.2 million with a net loss of US$72.9 million, and earnings have declined significantly over the past five years. Despite a P/S ratio lower than industry averages, the current share price is above its DCF fair value, indicating that any investment thesis relies on future profitability recovery rather than present earnings strength.
AVANOS MEDICAL, INC. SEC 10-K Report
Avanos Medical, Inc. has released its 2025 Form 10-K report, detailing a 1.9% increase in net sales to $701.2 million, largely due to growth in its Specialty Nutrition Systems and Pain Management and Recovery segments. The company reported a reduced net loss of $(72.9) million, down from $(392.1) million in 2024, attributed to lower impairment charges. Avanos is continuing its transformation process through 2026, including strategic acquisitions and divestitures, while facing challenges such as intense competition, technological demands, and regulatory risks.
Avanos Medical Inc announces the expansion of its transformation plan, expecting these initiatives to deliver incremental annualized savings of $15 million to $20 million by the end of 2026.
Avanos Medical Inc. has announced the expansion of its transformation plan, targeting incremental annualized savings of $15 million to $20 million by the end of 2026. This strategy aims to enhance operational efficiency, optimize cost structure, and strengthen the company's competitiveness in the medical device market. The plan involves systematic business restructuring and process improvements to create sustainable value for shareholders.
